H1512

Haloperidol

≥98% (TLC), powder, dopamine receptor antagonist

• Synonyme(s) : 4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone, 4-[4-(4-Chlorophenyl)-4-hydroxypiperidino]-4′-fluorobutyrophenone, 4-[4-(p-Chlorophenyl)-4-hydroxypiperidino]-4′-fluorobutyrophenone
• Formule empirique (notation de Hill): C₂₁H₂₃ClFNO₂
• Numéro CAS: 52-86-8
• Poids moléculaire : 375.86
• Numéro CE : 200-155-6
• Numéro MDL: MFCD00051423
• Code UNSPSC : 12352200
• ID de substance PubChem : 24277917
• Nomenclature NACRES : NA.77

Propriétés

• product name: Haloperidol, powder
• Forme: powder
• Couleur: white
• Solubilité: 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 0.39 mg/mL; 0.1 M HCl: 3 mg/mL; DMSO: soluble; H₂O: insoluble; ethanol: soluble
• Auteur: Johnson & Johnson
• Chaîne SMILES: OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c3ccc(Cl)cc3
• InChI: 1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
• Clé InChI: LNEPOXFFQSENCJ-UHFFFAOYSA-N
• Informations sur le gène: human ... ABCB1(5243) , ADRA1A(148) , ADRA2A(150) , ADRA2C(152) , CHRM1(1128) , DRD2(1813) , DRD3(1814) , DRD4(1815) , EBP(10682) , HRH1(3269) , HTR2A(3356) , HTR2C(3358) , HTR7(3363) , KCNH1(3756) , KCNH2(3757) , PRNP(5621) ; rat ... Adra1a(29412) , Adra2a(25083) , Chrm1(25229) , Chrm2(81645) , Drd1a(24316) , Drd2(24318) , Drd3(29238) , Drd4(25432) , Hrh1(24448) , Htr1a(24473) , Htr1b(25075) , Htr2a(29595) , Htr2c(25187) , Oprs1(29336) , Slc6a3(24898) , Slc6a4(25553)

Description

Application

Haloperidol has been used:

• in ethanol to serves as an inhibitor of Erg2p
• to address the mechanism of haloperidol in ferroptosis using hepatocellular carcinoma cells: Hep G2 and Huh-7 cell lines
• in receptor internalization assay
• as an antipsychotic drug in Dulbecco′s Modified Eagle medium

Actions biochimiques/physiologiques

Haloperidol is a butyrophenone antipsychotic. It is also classified as a neuroleptic (powerful tranquilizer). Haloperidol acts as a D2, D3, and D4 dopamine receptor antagonist and thus causes Parkinson′s disorder. It also has a negative effect on the central nervous system.

Caractéristiques et avantages

This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Informations sur la sécurité

• Pictogrammes: GHS06,GHS08
• Mention d'avertissement: Danger
• Mentions de danger: H301,H315,H317,H319,H335,H361
• Conseils de prudence: P202 - P261 - P280 - P301 + P310 - P302 + P352 - P305 + P351 + P338
• Classification des risques: Acute Tox. 3 Oral - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
• Organes cibles: Respiratory system
• Code de la classe de stockage: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• Classe de danger pour l'eau (WGK): WGK 3
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable